JPWO2021061708A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021061708A5 JPWO2021061708A5 JP2022518208A JP2022518208A JPWO2021061708A5 JP WO2021061708 A5 JPWO2021061708 A5 JP WO2021061708A5 JP 2022518208 A JP2022518208 A JP 2022518208A JP 2022518208 A JP2022518208 A JP 2022518208A JP WO2021061708 A5 JPWO2021061708 A5 JP WO2021061708A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- chain variable
- acid sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 120
- 239000012634 fragment Substances 0.000 claims description 64
- 210000004027 cell Anatomy 0.000 claims description 54
- 239000000427 antigen Substances 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 238000011467 adoptive cell therapy Methods 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 241000282465 Canis Species 0.000 claims description 6
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962904272P | 2019-09-23 | 2019-09-23 | |
| US62/904,272 | 2019-09-23 | ||
| PCT/US2020/052121 WO2021061708A1 (en) | 2019-09-23 | 2020-09-23 | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022548777A JP2022548777A (ja) | 2022-11-21 |
| JPWO2021061708A5 true JPWO2021061708A5 (https=) | 2023-09-06 |
| JP2022548777A5 JP2022548777A5 (https=) | 2023-09-06 |
| JP7603670B2 JP7603670B2 (ja) | 2024-12-20 |
Family
ID=74881697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518208A Active JP7603670B2 (ja) | 2019-09-23 | 2020-09-23 | マウスおよびヒト線維芽細胞活性化タンパク質（ｆａｐ）と交差反応するイヌ線維芽細胞活性化タンパク質に対するモノクローナル抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12139550B2 (https=) |
| EP (1) | EP4041290A4 (https=) |
| JP (1) | JP7603670B2 (https=) |
| KR (1) | KR20220066090A (https=) |
| CN (1) | CN114761036B (https=) |
| AU (1) | AU2020352986A1 (https=) |
| BR (1) | BR112022005404A2 (https=) |
| CA (1) | CA3151438A1 (https=) |
| IL (1) | IL291341A (https=) |
| MX (1) | MX2022003465A (https=) |
| WO (1) | WO2021061708A1 (https=) |
| ZA (1) | ZA202203460B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| US20240199762A1 (en) * | 2021-04-23 | 2024-06-20 | Philogen S.P.A | Anti-fibroblast activation protein antibodies |
| WO2025005966A1 (en) * | 2023-06-29 | 2025-01-02 | Edge Animal Health, Inc. | Urine pcr assay and use thereof to diagnose and stage feline chronic kidney disease |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| CN118388652B (zh) * | 2024-06-21 | 2025-03-04 | 杭州新东澳生物科技有限公司 | 抗成纤维细胞活化蛋白的单克隆抗体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| ATE446366T1 (de) | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
| CA2533593A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| EP2628753A1 (en) | 2008-01-24 | 2013-08-21 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| EP2483316A1 (en) * | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| HUE036077T2 (hu) * | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US20160136272A1 (en) * | 2013-05-14 | 2016-05-19 | Innate Pharma | Methods for restoring corticosteroid sensitivity |
| AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| CA2921639A1 (en) | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| GB201500875D0 (en) * | 2015-01-19 | 2015-03-04 | Philogen Spa | Antibodies for treatment and diagnosis |
| TWI736575B (zh) | 2016-01-22 | 2021-08-21 | 美商默沙東藥廠 | 抗凝固因子ｘｉ抗體 |
| MY209117A (en) | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| WO2018105560A1 (ja) * | 2016-12-07 | 2018-06-14 | 国立大学法人大阪大学 | Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬 |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| US11786551B2 (en) * | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| CN109796532B (zh) | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| MA51428A (fr) | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| KR102804816B1 (ko) | 2018-03-09 | 2025-05-09 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd73 항체 및 이의 용도 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| EP4228601A4 (en) | 2020-10-13 | 2025-08-06 | Univ Pennsylvania | IN VIVO TARGETING OF FIBROSIS BY TARGETING ANTI-CD5 IN MRNA-LNP FAP-CAR-T |
-
2020
- 2020-09-23 WO PCT/US2020/052121 patent/WO2021061708A1/en not_active Ceased
- 2020-09-23 JP JP2022518208A patent/JP7603670B2/ja active Active
- 2020-09-23 KR KR1020227011620A patent/KR20220066090A/ko active Pending
- 2020-09-23 CN CN202080079394.8A patent/CN114761036B/zh active Active
- 2020-09-23 US US17/029,284 patent/US12139550B2/en active Active
- 2020-09-23 BR BR112022005404A patent/BR112022005404A2/pt unknown
- 2020-09-23 MX MX2022003465A patent/MX2022003465A/es unknown
- 2020-09-23 EP EP20869609.6A patent/EP4041290A4/en active Pending
- 2020-09-23 CA CA3151438A patent/CA3151438A1/en active Pending
- 2020-09-23 AU AU2020352986A patent/AU2020352986A1/en active Pending
-
2022
- 2022-03-14 IL IL291341A patent/IL291341A/en unknown
- 2022-03-24 ZA ZA2022/03460A patent/ZA202203460B/en unknown
-
2024
- 2024-02-28 US US18/589,804 patent/US20240384004A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112321715B (zh) | 抗trop2纳米抗体及其制备方法和应用 | |
| CN111018986B (zh) | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 | |
| US10077305B2 (en) | Antibodies against PD-1 and uses thereof | |
| CN112703013B (zh) | Cd3抗原结合片段及其应用 | |
| KR101837053B1 (ko) | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 | |
| JP2022028918A (ja) | 抗ｒｏｒ１抗体およびその使用 | |
| CN114761036B (zh) | 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体 | |
| JP7646768B2 (ja) | 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途 | |
| KR102860436B1 (ko) | 메소텔린 특이적 항체 및 이의 용도 | |
| CN113004408B (zh) | 抗人程序死亡因子-1单克隆抗体 | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| CN116568706A (zh) | Gpc3特异性抗体及其用途 | |
| JPWO2021061708A5 (https=) | ||
| CN116925229B (zh) | 一种靶向gprc5d的抗体及其应用 | |
| EP4238990A1 (en) | Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof | |
| CN120897754A (zh) | 嵌合抗原受体 | |
| EP4663661A1 (en) | Anti-cdh6 antibody and use thereof | |
| CN110615841B (zh) | 抗人cd47单克隆抗体及其应用 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| CN115947855B (zh) | 抗cd24抗体的制备及其用途 | |
| TWI793451B (zh) | 個人化癌症免疫治療 | |
| WO2024120526A1 (zh) | 抗ilt4抗体及其制备方法和应用 | |
| CN112794900B (zh) | cBIN1抗体及其应用 | |
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 | |
| EP4328243A1 (en) | Asymmetric antibody with improved cytotoxicity against cancer cell |